Protective Role of the ACE2/Ang-(1–9) Axis in Cardiovascular Remodeling

Rho kinase inhibition activates the homologous angiotensin-converting enzyme-angiotensin-(1–9) axis in experimental hypertension

(2011) María P Ocaranza et al.   JOURNAL OF HYPERTENSION

Mas receptors in modulating relaxation induced by perivascular adipose tissue

(2011) Robert M.K.W. Lee et al.   LIFE SCIENCES

Angiotensin-Converting Enzyme 2 Suppresses Pathological Hypertrophy, Myocardial Fibrosis, and Cardiac Dysfunction

(2010) JiuChang Zhong et al.   CIRCULATION

Angiotensin-(1–7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy

(2010) Elena Velkoska et al.   CLINICAL SCIENCE

ACE2: more of Ang-(1–7) or less Ang II?

(2010) Carlos M Ferrario   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

ACE2–angiotensin-(1–7)–Mas axis and oxidative stress in cardiovascular disease

(2010) Luiza A Rabelo et al.   HYPERTENSION RESEARCH

Angiotensin-(1–9) regulates cardiac hypertrophy in vivo and in vitro

(2010) Maria Paz Ocaranza et al.   JOURNAL OF HYPERTENSION

Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor

(2010) M. Flores-Muñoz et al.   JOURNAL OF PHYSIOLOGY-LONDON

When simple agonism is not enough: Emerging modalities of GPCR ligands

(2010) Nicola J. Smith et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Vascular wall ACE is not required for atherogenesis in ApoE−/− mice

(2009) Daiana Weiss et al.   ATHEROSCLEROSIS

Soluble Angiotensin-Converting Enzyme 2 in Human Heart Failure: Relation With Myocardial Function and Clinical Outcomes

(2009) Slava Epelman et al.   JOURNAL OF CARDIAC FAILURE

Endothelium-dependent relaxation factor released by perivascular adipose tissue

(2009) Robert MKW Lee et al.   JOURNAL OF HYPERTENSION

Angiotensin-(1–7) and the G Protein-Coupled Receptor Mas Are Key Players in Renal Inflammation

(2009) Vanesa Esteban et al.   PLoS One

(Pro)renin receptors: are they biologically relevant?

(2008) AH Jan Danser   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor

(2008) Rebecca A. Lew et al.   EXPERIMENTAL PHYSIOLOGY

Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis

(2008) Robson A. S. Santos et al.   EXPERIMENTAL PHYSIOLOGY

Cardiac Overexpression of Angiotensin Converting Enzyme 2 Protects the Heart From Ischemia-Induced Pathophysiology

(2008) Shant Der Sarkissian et al.   HYPERTENSION

Transgenic Angiotensin-Converting Enzyme 2 Overexpression in Vessels of SHRSP Rats Reduces Blood Pressure and Improves Endothelial Function

(2008) Brit Rentzsch et al.   HYPERTENSION

Increased Expression of Angiotensin Converting Enzyme 2 in Conjunction with Reduction of Neointima by Angiotensin II Type 1 Receptor Blockade

(2008) Michiya IGASE et al.   HYPERTENSION RESEARCH

Over-expression of angiotensin II type 2 receptor (agtr2) reduces atherogenesis and modulates LOX-1, endothelial nitric oxide synthase and heme-oxygenase-1 expression

(2007) Changping Hu et al.   ATHEROSCLEROSIS

Over-expression of angiotensin II type 2 receptor (agtr2) decreases collagen accumulation in atherosclerotic plaque

(2007) Abhijit Dandapat et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS